Type of Cancer
Phase
Division (Location)
Study ID
NCT#
Brief Description
Phase IIA, open-label study, of AGEN1884 in combination with pembrolizumab in subjects with stage IV NSCLC whose tumors have high PD-L1 expression (>50%) and no EGFR or ALK mutations
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.